Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

New biotech Naia gets exclusive global license to two Amunix compounds

Executive Summary

Amunix Operating Inc. licensed newly created Naia Ltd. exclusive global rights to its Phase I glucagon-like peptide-1 (GLP-1) receptor agonist GLP-1-XTEN (renamed NB1001) for Type II diabetes, and preclinical GLP-2-XTEN (NB1002), a GLP-2 receptor agonist for short bowel syndrome.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies